1 transaction in EDIT reported by 1 member of Congress under the STOCK Act, most recent trade Apr 10, 2023. Reported transactions, not recommendations.
About Editas Medicine, Inc. (EDIT): stock profile, AI score and financials
Editas Medicine, Inc. (EDIT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores EDIT at 33.5/100 on a composite quality score built from its SEC filings, placing it at rank #2,368 of 2,925 stocks — the bottom half of the AI-ranked universe. EDIT scores in the top quartile across institutional flow (99.2), revenue growth (98.0). Areas of concern include earnings quality (2.5) and free cash flow (4.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Editas Medicine, Inc. reports quarterly revenue of $11.9M, net income of $-18.2M, an operating margin of -156.1%. Top institutional holders of EDIT by reported 13-F value include TCG Crossover Management, BlackRock, RA CAPITAL MANAGEMENT, L.P., based on the most recent SEC filings. EDIT trades on the Nasdaq exchange and files with the SEC under CIK 1650664. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EDIT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Editas Medicine, Inc. directly from SEC EDGAR.